HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zinc compounds as therapeutic agents in peptic ulcer.

Abstract
Zinc acexamate (ZAC) is the first zinc compound developed and marketed for use in the therapy of peptic ulcer. ZAC is active in several ulcer experimental models. This action is secondary to an effect on both aggressive and defensive mucosal factors. ZAC reduces acid and peptic secretion, increases mucus secretion, protects mucosa from disruption by aspirin and reverses the reduction of blood flow caused by noradrenaline. Clinically, ZAC has proven to be a useful drug in the healing of peptic ulcer. Reduction of inflammatory associated processes of peptic ulcer, which has not been seen with H2-blockers, suggests that ZAC may be highly effective in preventing ulcer relapse. These properties, together with its good safety profile, indicate that ZAC would be an interesting option in the treatment of peptic ulcer.
AuthorsJ E Baños, O Bulbena
JournalMethods and findings in experimental and clinical pharmacology (Methods Find Exp Clin Pharmacol) Vol. 11 Suppl 1 Pg. 117-22 ( 1989) ISSN: 0379-0355 [Print] Spain
PMID2657281 (Publication Type: Journal Article, Review)
Chemical References
  • Zinc
Topics
  • Humans
  • Male
  • Peptic Ulcer (drug therapy)
  • Zinc (adverse effects, pharmacokinetics, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: